LGND · Ligand Pharmaceuticals Incorporated

The thesis

Ligand Pharmaceuticals collects royalties on other companies' drugs, and that income beat expectations in the third quarter. The 8 December 2026 Investor Day settles the next step: a new five-year outlook and a check on the projected $1.50 of 2027 adjusted earnings per share (EPS) from the XOMA acquisition.

Ligand's 29 October 2026 report showed royalty revenue of $70.3 million, up 51% from $46.6 million a year earlier. Adjusted EPS of $2.67 beat a $2.38 estimate (Benzinga). Full-year adjusted EPS guidance rose to $9.50–$9.75 from $9.00–$9.50.

The company reaffirmed revenue guidance of $270–$310 million and royalty guidance of $225–$250 million in its 8-K release, although a 29 October 2026 Benzinga headline described a lower sales range. The view here is that the unchanged range understates the fourth quarter. That view fails if full-year royalty revenue lands in the lower half of the range.

The narrative is maturing: analysts raised targets after the 29 October 2026 beat, yet the shares closed at $299.00 on 5 November 2026, below the $311.73 close of 27 October 2026.

Bullish and bearish views on Ligand Pharmaceuticals Incorporated

The bull case on Ligand Pharmaceuticals Incorporated (LGND), in brief: Filspari is now the largest royalty. The bear case: Reported earnings showed a loss.

Bull case

• Filspari is now the largest royalty. Ligand estimated its third-quarter Filspari royalty at $16.8 million, up 85%, ahead of Kyprolis at $10.5 million (Q3 call, 29 October 2026). Travere reported on 2 November 2026 that U.S. Filspari net sales rose 120% to $200.2 million.
• Guidance looks cautious against the run rate. Nine-month royalty revenue was $161.3 million against the $225–$250 million full-year range (Ligand 8-K, 29 October 2026). The chief financial officer said on the call that the company has "a high level of confidence" in the mid-to-upper part of the implied fourth-quarter range.
• XOMA closed on 14 July 2026, so the fourth quarter is its first full quarter.
• Analyst targets rose after the report. Citigroup raised its target to $402 from $397 on 5 November 2026. RBC moved to $357 from $345 and Oppenheimer to $346 from $334 on 30 October 2026, and Oppenheimer called the unchanged guidance conservative (Finimize).
• Capital is available for new royalties. Ligand reported about $750 million of deployable capital on 29 October 2026, including equity investments and credit availability. The chief executive said on the call that deploying "somewhere below $200 million" a year would sustain growth for a significant period.

Bear case

• Reported earnings showed a loss. The third-quarter net loss under generally accepted accounting principles was $28.5 million, or $1.43 per share, against net income of $117.3 million a year earlier (Ligand 8-K, 29 October 2026). Total revenue and income fell 32% to $78.7 million because the prior year included $53.1 million of Pelthos income.
• Inventory lifted some Filspari sales. Travere said on its Q3 call that specialty pharmacy orders pushed inventory above historical levels, contributing about $8 million of third-quarter net sales (reported 2 November 2026). Ligand's $16.8 million royalty estimate came from analyst consensus before Travere reported, and any difference is corrected in the fourth quarter.
• The fourth quarter carries the non-royalty lines. Third-quarter Captisol sales fell to $7.9 million from $10.7 million, and contract revenue was $0.5 million, against full-year ranges of $35–$40 million and $10–$20 million (Ligand 8-K, 29 October 2026). Management said order and milestone timing can move revenue between quarters.
• Kyprolis is still shrinking. Amgen reported third-quarter Kyprolis sales of $330 million, down 8% from $359 million. The decline was narrower than the 17% drop to $314 million in the second quarter.
• Pelthos takes more capital. Ligand agreed on 30 October 2026 to a $33.75 million purchase of Pelthos preferred stock and warrants, $30.075 million of it in cash, tied to the Castle Creek merger (Schedule 13D/A, 3 November 2026).
• Insiders have sold into the range. Company news carried an insider sale headline on 4 November 2026, without detail in the headline. CFO Octavio Espinoza sold 31,641 shares at $292.06 and director Jason Haas sold 7,138 at $292.81 in August (Form 4 summary, 12 August 2026).
• Warrant dilution starts near the current price. Management said on the Q3 call that warrants dilute above roughly $294 for the 2030 notes and $524 for the 2031 notes.

Price setup

The shares closed at $299.00 on 5 November 2026, 7.4% below the 52-week high of $322.75 in adjusted daily closes. They are up 1.1% over three months, so the third-quarter beat has not yet produced a new high. The 14-day relative strength index, a momentum gauge on a 0–100 scale, is 51.8.

Crowding evidence is modest. Momentum is neutral, and the third-quarter report is already out, so no earnings date is imminent. The observable pressure is insider selling, including Andrew Reardon's 5,000 shares on 3 September 2026 under a pre-arranged trading plan (InsiderTrades).

The $262 repurchase price Ligand disclosed on 6 August 2026 remains the invalidation level. A weekly close below it would put the shares under a price the company itself paid.

Catalysts, next 30 days

• 8 December 2026: Ligand Investor Day. It updates the five-year outlook and gives the next dated check on the $1.50 XOMA figure. This falls just past the 30-day window, and the case turns on it.
• 28 February 2027: U.S. Food and Drug Administration decision date for Palvella's Qtorin rapamycin in microcystic lymphatic malformations (Ligand 8-K, 29 October 2026).

Elapsed catalysts

• November 2026 (dates not confirmed here): Ligand said on 27 October 2026 that it would take part in investor conferences this month. No company results date falls inside the next 30 days. (passed 10d ago)
• Mid-December 2026: Rezolute expects topline results for ersodetug in tumor hyperinsulinism (Ligand 8-K, 29 October 2026). (passed 8d ago)

What would change the view

The case breaks if royalty growth fails to carry the guidance. A cut to 2026 royalty revenue guidance below $225 million would show that. So would a reduced or withdrawn $1.50 XOMA figure at the 8 December 2026 Investor Day.

A large negative correction to Ligand's estimated Filspari royalty in the fourth quarter would weaken the case. So would Kyprolis sales falling back below the $314 million reported for the second quarter while Filspari growth slows sharply from 120%.

On price, a weekly close below $262, the repurchase price Ligand disclosed on 6 August 2026, ends the thesis.

What it trades with

Ligand's royalty line follows partners' reported sales, so Travere and Amgen reports move the inputs before Ligand reports its own quarter. Palvella, Rezolute and Mirum carry clinical or regulatory events that feed into Ligand's pipeline value. Management said on the 29 October 2026 call that not every study is expected to succeed.

Pelthos is a separate exposure. Ligand's 1,500,000 common shares are about 38.2% of Pelthos common stock (Schedule 13D/A, 3 November 2026), and the Castle Creek merger agreement may be terminated if the merger has not closed by 1 February 2027, extendable to 31 March 2027.